Compare Aon PLC (AON) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aon PLC vs BioNano Genomics Inc — how do they compare? Aon PLC trades at $351.28 (market cap $75.61B), while BioNano Genomics Inc trades at $1.19 (market cap $13.66M). The key difference: Aon PLC is far larger — about 5535.1× BioNano Genomics Inc's market cap, and Aon PLC pays a 0.92% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| AON | BNGO | |
|---|---|---|
Market Cap | $75.61B | $13.66M |
Sector | Financials | Health |
52-Week High | $381.26 | $4.92 |
52-Week Low | $308.22 | $1.06 |
Enterprise Value | $90.22B | $16.26M |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AON trades at $351.56, down 1.52% on the day, with a neutral technical signal and strong fundamentals including a 22.27% net income margin and consistent earnings beats. The stock shows robust profitability with ROE of 44.88% and revenue growth to $17.18B in 2025, though valuation multiples like a P/E of 19.65 and P/S of 4.37 reflect premium pricing. Recent news highlights institutional buying and Q2 2026 earnings beat, with organic revenue growth of 5% supporting positive sentiment.
Outlook remains favorable given earnings momentum and analyst consensus price target of $410, but risks include high valuation sensitivity and debt levels. The stock offers growth exposure with upside potential, balanced by execution risks in a competitive insurance brokerage sector.
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aon PLC
Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in 120 countries around the world.
Read more on AON →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
